Fig. 5: Trial search results.
From: Gene- and immune-targeted therapy combinations using dual-matched biomarkers for patient selection
A PRISMA flow chart of the trial search (See Methods). Search was conducted on Mar 24, 2023, for ClinicalTrials.gov, using the search terms “(PD-1 OR PD-L1 OR CTLA4 OR LAG3) AND (targeted OR combination)” with a start date of Jan 1, 2018. After the screening, 1389 records did not meet the inclusion criteria and were therefore excluded from the further assessment. B Proportion of trials that utilized biomarkers for both the immune checkpoint inhibitor and the gene-targeting agent. Of the 314-trials assessed, 235 trials (75% [235/314]) did not assess biomarkers for patient inclusion. Forty-six trials checked gene alterations or immunohistochemistry for the targeted gene. The details of the four trials that assessed biomarkers for both the immune- and the gene-targeted therapy are presented in Supplementary Table 4. ICI immune checkpoint inhibitor.
